StockData
Interpace Biosciences, Inc. logo

Interpace Biosciences, Inc. (IDXG) stock

IDXGOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/30
$5.00−0.15 (-2.91%)

Close on Oct 19, 2026Market cap $138.57MP/E 5.6Yield –

Interpace Biosciences operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Interpace Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was $4.46M, down 11.8% year over year. For fiscal 2025 it was $5.83M, up 25.5% from the year before. The highest annual figure on record is $16.35M in fiscal 2010.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.83M+25.5%
FY2024Dec 31, 2024$4.65M+22.6%
FY2023Dec 31, 2023$3.79M–
FY2022Dec 31, 2022-$7.69M–
FY2021Dec 31, 2021-$8.72M–
FY2020Dec 31, 2020-$13.98M–
FY2019Dec 31, 2019-$18.96M–
FY2018Dec 31, 2018-$8.67M–
FY2017Dec 31, 2017-$15.26M–
FY2016Dec 31, 2016-$7.61M–
FY2015Dec 31, 2015-$19.84M–
FY2014Dec 31, 2014-$16.38M–
FY2013Dec 31, 2013-$3.51M–
FY2012Dec 31, 2012-$10.29M-618.2%
FY2011Dec 31, 2011$1.99M-87.9%
FY2010Dec 31, 2010$16.35M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$98.00K-81.2%
Q1 FY2026Mar 31, 2026$283.00K-77.1%
Q4 FY2025Dec 31, 2025$2.14M+80.6%
Q3 FY2025Sep 30, 2025$1.94M-8.4%
Q2 FY2025Jun 30, 2025$520.00K-63.0%
Q1 FY2025Mar 31, 2025$1.24M–
Q4 FY2024Dec 31, 2024$1.18M+3.9%
Q3 FY2024Sep 30, 2024$2.12M+91.5%
Q2 FY2024Jun 30, 2024$1.40M+241.6%
Q1 FY2024Mar 31, 2024-$58.00K-105.1%
Q4 FY2023Dec 31, 2023$1.14M–
Q3 FY2023Sep 30, 2023$1.11M–
Q2 FY2023Jun 30, 2023$411.00K–
Q1 FY2023Mar 31, 2023$1.13M–
Q4 FY2022Dec 31, 2022-$276.00K–
Q3 FY2022Sep 30, 2022-$3.24M–
Q2 FY2022Jun 30, 2022-$2.92M–
Q1 FY2022Mar 31, 2022-$1.25M–
Q4 FY2021Dec 31, 2021-$1.22M–
Q3 FY2021Sep 30, 2021-$676.00K–
Q2 FY2021Jun 30, 2021-$1.82M-505.1%
Q1 FY2021Mar 31, 2021-$5.01M–
Q4 FY2020Dec 31, 2020-$1.58M–
Q3 FY2020Sep 30, 2020-$5.72M–
Q2 FY2020Jun 30, 2020$449.00K–
Q1 FY2020Mar 31, 2020-$7.12M–
Q4 FY2019Dec 31, 2019-$6.40M–
Q3 FY2019Sep 30, 2019-$4.77M–
Q2 FY2019Jun 30, 2019-$4.83M–
Q1 FY2019Mar 31, 2019-$2.96M–
Q4 FY2018Dec 31, 2018-$1.87M–
Q3 FY2018Sep 30, 2018-$1.77M–
Q2 FY2018Jun 30, 2018-$2.53M–
Q1 FY2018Mar 31, 2018-$2.49M–
Q4 FY2017Dec 31, 2017-$2.38M–
Q3 FY2017Sep 30, 2017-$4.31M–
Q2 FY2017Jun 30, 2017-$4.42M–
Q1 FY2017Mar 31, 2017-$4.15M–
Q4 FY2016Dec 31, 2016-$990.00K–
Q3 FY2016Sep 30, 2016-$1.35M–

More Interpace Biosciences figures

See a number that looks wrong?